RetiSpec is an artificial intelligence (AI) medical imaging company developing tools for the early detection of disease biomarkers in the eye.
Our goal is to enable widespread early detection of Alzheimer’s disease with accessible and scalable screening.
The company is headquartered in Toronto, Canada, and is part of the Ontario Brain Institute (OBI), Biomedical Zone, NEXT Canada, Ontario Centre of Excellence and The Centre for Aging and Brain Health Innovation (CABHI)’s network of companies.
Our goal is to enable widespread early detection of Alzheimer’s disease with accessible and scalable screening.
The company is headquartered in Toronto, Canada, and is part of the Ontario Brain Institute (OBI), Biomedical Zone, NEXT Canada, Ontario Centre of Excellence and The Centre for Aging and Brain Health Innovation (CABHI)’s network of companies.
Location: Canada, Ontario, Toronto
Employees: 1-10
Total raised: $10M
Founded date: 2016
Investors 4
| Date | Name | Website |
| - | Berkeley S... | skydeck.be... |
| - | MassChalle... | masschalle... |
| - | Verge Heal... | verge.fund... |
| - | NEXT Canad... | directory.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.07.2024 | Series A | $10M | - |
Mentions in press and media 3
| Date | Title | Description |
| 29.07.2024 | RetiSpec Closes $10M USD in Series A Funding | RetiSpec Inc., a Toronto, Canada-based innovator in AI-driven eye diagnostics for brain health, closed a $10M USD Series A financing. The round was led by iGan Partners and included new strategic investors, Eli Lilly and Company and Topcon ... |
| 26.07.2024 | RetiSpec Closes $10M USD to Advance Commercialization of its AI-Driven Eye Test for Detection of Alzheimer's Disease | TORONTO, July 26, 2024 /PRNewswire/ - RetiSpec Inc., an innovator in AI-driven eye diagnostics for brain health, announced the successful closing of its $10M USD Series A financing. This funding will enable RetiSpec to accelerate the commer... |
| - | RetiSpec | “RetiSpec is a medical imaging company using advanced AI for the detection of neurodegenerative diseases through hyperspectral imaging of the eye.” |